Potential strategies for inflammatory mediator manipulation: retrospect and prospect.
Sepsis syndrome and septic shock remain significant causes of morbidity and mortality. To date, clinical trials of novel agents to treat sepsis have failed to demonstrate clinical efficacy despite considerable animal data to suggest a positive therapeutic benefit. This article reviews the recent major clinical trials on sepsis and discusses the hypotheses on which these therapies are based and the critical issues associated with clinical sepsis. Recommendations for future clinical trials on sepsis are made.
Fisher
C J
CJ
Department of Pulmonary and Critical Care Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195, U.S.A.
Zheng
Y
Y
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004731:Endotoxins / Q000037:antagonists & inhibitors / Q000502:physiology; D005544:Forecasting; D006801:Humans; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors* / Q000502:physiology; D007375:Interleukin-1 / Q000037:antagonists & inhibitors / Q000502:physiology; D009102:Multiple Organ Failure / Q000503:physiopathology / Q000628:therapy*; D012772:Shock, Septic / Q000503:physiopathology / Q000628:therapy*; D018746:Systemic Inflammatory Response Syndrome / Q000503:physiopathology / Q000628:therapy*; D017211:Treatment Failure; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000502:physiology
D000911:Antibodies, Monoclonal; D004731:Endotoxins; D018836:Inflammation Mediators; D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha